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Abstract
The essential fatty acids, linoleic acid and arachidonic acid play an important role in pancreatic
cancer development and progression. These fatty acids are metabolized to eicosanoids by
cyclooxygenases and lipoxygenases. Abnormal expression and activities of both cyclooxygenases
and lipoxygenases have been reported in pancreatic cancer. In this article, we aim to provide a brief
summary of (1) our understanding of the roles of these enzymes in pancreatic cancer tumorigenesis
and progression; and (2) the potential of using cyclooxygenase and lipoxygenase inhibitors for
pancreatic cancer treatment and prevention.
Review
Molecular studies of the well-known relationship between
polyunsaturated fatty acid metabolism and carcinogenesis
have revealed novel molecular targets for cancer chemo-
prevention and treatment [1–4]. Polyunsaturated fatty ac-
ids are esterified in membrane phospholipids and
triglycerides in all mammalian tissues [5]. In this form,
they are usually not substrates for metabolizing enzymes,
but serve the function of sustaining membrane fluidity as
well as that of substrate storage [5]. Oxidative metabolism
of these fatty acids to prostaglandins, hydroxy-fatty acids
and leukotrienes, collectively referred to as eicosanoids,
depends on the availability of free, non-esterified fatty ac-
ids [5]. These fatty acids are substrates for three distinc-
tively different enzymatic pathways, cyclooxygenase
(COX), lipoxygenase (LOX) and epoxygenase [5]. This ar-
ticle presents a new perspective about the role of cycloox-
ygenase and lipoxygenase on pancreatic cancer
development and growth, the underlying mechanisms by
which they mediate these effects and their potential as tar-
gets for pancreatic cancer prevention and treatment.
Cyclooxygenases and lipoxygenases: the key 
metabolic enzymes for arachidonic acid and lino-
leic acid
Cyclooxygenases
Cyclooxygenase (COX) which has two isoforms, COX-1
and COX-2 is the enzyme that catalyzes the rate-limiting
step in prostaglandin synthesis, converting arachidonic
acid into prostaglandin H2, which is then further metabo-
lized to prostaglandin E2 (PGE2), PGF2α, PGD2 and other
eicosanoids [5,6]. COX-1 is constitutively expressed in
many tissues and plays a role in tissue homeostasis. COX-
2, which can be expressed in a variety of cells and tissues,
is an inducible isoform the expression of which is stimu-
lated by growth factors, cytokines, and tumor promoters.
Despite the structural similarity between the two isofor-
ms, COX-1 and COX-2 differ substantially in the regula-
tion of their expression and their roles in tissue biology
and disease [5,6]. In the past decade, tremendous progress
has been made in understanding the functional roles of
COX in cancer development and growth. COX-2 is up-reg-
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ulated in many cancer types, including the colon, breast,
lung, pancreas, and esophagus as well as squamous cell
carcinoma of the head and neck [7–11]. COX-2 specific
inhibitors inhibit cell growth in a number of tumors in-
cluding skin, colonic, gallbladder, esophageal and pancre-
atic cancer cells [7–11]. Studies from both COX-2
transgenic and COX-2 knockout mice confirm that COX-
2 plays a key role in colonic cancer development [12].
However, a recent study in COX-1 deficient mice, showed
that lack of COX-1 also significantly reduced intestinal tu-
morigenesis in min mice, a phenotype similar to that of
COX-2-/-  mice [12]. Furthermore, there may be other
forms of COX enzymes, making things even more compli-
cated. Simmons and colleagues, recently identified an en-
zyme that they have called cyclooxygenase-3, or COX-3.
COX-3 is an isoform of COX-1, but is expressed in cells in
an inducible manner [13]. COX-3 is selectively inhibited
by different NSAIDs and has a high sensitivity to acetami-
nophen. However, whether COX-3 is involved in tumori-
genesis is unknown [13].
Lipoxygenases
Lipoxygenases possess regiospecificity during interaction
with substrates and on this basis have been designated as
arachidonate 5-, 8, 12-, 15-lipoxygenase (5-LOX, 8-LOX,
12-LOX, and 15-LOX) [5,13–17]. The four distinct en-
zymes insert oxygen at carbon 5, 8, 12 or 15 of arachido-
nate acid. The primary products are 5S-, 12S-, or 15S-
hydroperoxyeicosatetraenoic acid (5-, 8-, 12-, or 15-
HPETE), which can be further reduced by glutathione per-
oxidase to the hydroxy forms (5-, 8-, 12-, 15-HETE) re-
spectively [5,13–17]. 5-LOX represents a dioxygenase that
possesses two distinct enzymatic activities leading to the
formation of LTA4. First it catalyzes the incorporation of
molecular oxygen into arachidonic acid (oxygenase activ-
ity), producing HPETE and subsequently forms the unsta-
ble epoxide LTA4 (LTA4 synthase activity) [5,6]. This is
followed by the insertion of molecular oxygen at position
C-5, converting LTA4  to either 5(S)-hydroxy-6-trans-
8,11,14-cis-eicosatetranoic acid (5-HETE) or leukotrienes.
Five Lipoxygenase Activating Protein (FLAP), which is a
18 kDa membrane-bound protein, plays an important
role in mediating the arachidonic catalytic activity of 5-
LOX [5,6]. FLAP activity can be blocked by the FLAP in-
hibitor, MK886 [5,6]. Hydrolytic attack of LTA4 by leuko-
triene A4  hydrolase yields LTB4, a potent neutrophil
chemoattractant and stimulator of leukocyte adhesion to
endothelial cells. LTC4 synthase catalyzes the conjugation
of LTA4 with glutathione to form LTC4 at the nuclear en-
velope. The peptide moiety of LTC4 is subject to extracel-
lular metabolism, forming LTD4 and LTE4 [5,6]. These
three leukotrienes comprising the cysteinyl leukotrienes,
before their structures were identified were known as the
"slow-reacting substance of anaphylaxis" named for their
slow and sustained smooth muscle contracting abilities
[5,6]. Accumulating evidence suggests that the 5-LOX
pathway has profound influence on the development and
progression of human cancers [18]. 5-LOX inhibitors have
chemopreventive effects in animal lung carcinogenesis
[19]. Furthermore, the 5-LOX pathway interacts with mul-
tiple intracellular signaling pathways that control cancer
cell proliferation [9]. Blockade of 5-LOX inhibits prostate
cancer cell proliferation while the 5-LOX metabolite, 5-
HETE stimulates prostate cancer cell growth [20]. Further-
more, the FLAP inhibitor, MK886 exerts a similar growth
inhibitory effect on cancer cell proliferation to 5-LOX in-
hibitors, further supporting a role for 5-LOX as a mediator
of cancer cell proliferation [21].
Three forms of 12-lipoxygenase have been identified, in-
cluding the leukocyte-type and platelet-type (both 12(S)
LOXs) as well as an epidermal form (also called 12(R)
LOX), with differences in tissue localization, substrate
specificities, immunogenicities and sequence homology
[14,15]. The "platelet-type" 12-LOX converts arachidonic
acid to 12-(S)-HETE while the "leukocyte type" 12-LOX
metabolizes arachidonic acid or linoleic acid to either
12(S)-HETE or 15(S)-HETE [14,15]. Both the leukocyte-
type and platelet-type12-LOX have been found in differ-
ent cancer tissues, including melanoma, prostate and epi-
dermal cancers [18]. Evidence indicates that 12-LOX is
involved in both cancer cell proliferation and survival
[15]. Inhibition of 12-LOX with either 12-LOX inhibitors
or a 12-LOX antisense oligonucleotide inhibits prolifera-
tion and induces apoptosis in carcinosarcoma cells, while
adding back the 12-LOX metabolite, 12(S)-HETE prevents
12-LOX inhibitor-induced apoptosis [22]. Expression of
12-LOX is also correlated with tumor cell metastasis.
12(S)-HETE directly stimulates prostate cancer cell migra-
tion. Clinically, the degree of 12-LOX expression in hu-
man prostate cancer correlates with the tumor grade and
stage and 12-LOX expression level is higher in metastatic
prostate cancers than in nonmetastatic ones [23].
Another arachidonic acid-metabolizing enzyme is 8-
lipoxygenase, which was cloned recently. This enzyme is
expressed in the skin after irritation or treatment with tu-
mor promoters [25]. To understand the function of the
product of 8-lipoxygenase, 8-hydroxyeicosatetraenoic
acid transgenic mice have been generated [26]. These ani-
mals show enhanced differentiation of epidermal kerati-
nocytes along with enhanced proliferation of the basal
cell population. While the function of 8-HPETE and 8-
HETE are unknown, their importance in tumor promoter-
elicited events is suggested by the finding that application
of the lipoxygenase inhibitor, eicosatetraenoic acid maxi-
mally inhibits tumor promotion when applied at the time
of maximum induction of 8-lipoxygenase [26,27]. Com-
pared with other LOX enzymes, 8-LOX has received little
attention for its role in carcinogenesis and cancer growth.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/10
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Expression and function of 8-LOX in pancreatic cancer
have not been investigated to date even though 8-LOX
cDNA and antibody are available [27].
15-lipoxygenase, which is distributed widely in tissues,
converts arachidonic acid to 15-HPETE which is then re-
duced by glutathione peroxidase to 15-HETE
[16,17,24,28]. There are two 15-LOX isoenzymes, 15-
LOX-1 and 15-LOX-2 [28]. The preferred substrate for 15-
LOX-1 is linoleic acid and for 15-LOX-2 is arachidonic ac-
id. 15-LOX-1 metabolizes linoleic acid to 13-S-HODE,
which differs from 15-LOX-2 which, as expected, converts
arachidonic acid to 15-HETE [28]. The role of 15-LOX in
cancer development is unclear and somewhat controver-
sial [28]. A series of studies from one group suggest that
the 15-LOX-1 product, 13-S-HODE enhances colonic tu-
morigenesis. 13-S-HODE enhances cell proliferation and
potentiates the mitogenic response to EGF in different cell
types [29,30]. These proposed effects, however, are not
consistent with other reports that 13-S-HODE did not en-
hance EGF-dependent DNA synthesis [28]. Indeed, Lipp-
man et al reported that 13-S-HODE induces apoptosis and
cell cycle arrest in colorectal cancer cells [31]. Evidence
also indicates that 15-S-HETE may have anti-tumorigenic
effects by antagonizing other LOX products, such as LTB4
and 12-S-HETE [28]. 15-HETE inhibits LTB4 production
and reduces LTB4 binding to its receptors and thereby
blocks cellular responses to LTB4. 15-HETE also blocks
platelet-type 12-LOX activity and reduces 5-LOX activity
in rat basophilic leukemia cells [28,32]. Different studies
have suggested that 15-S-HETE may suppress apoptosis,
or have no effect on apoptosis in cancer cells [28]. A recent
study has shown that 15-S-HETE inhibits proliferation in
PC3 prostate carcinoma cells, possibly through activation
of PPARγ [33]. Therefore, further studies are required to
clarify the role of 15-LOX in tumorigenesis and cancer
growth.
Cyclooxygenases and lipoxygenases in pancreat-
ic cancer
COX inhibition and pancreatic cancer incidence, the epi-
demiological observations
Tumorigenesis is a complex process and understanding its
mechanisms is the key to designing effective targeted ther-
apies. Several epidemiologic studies have shown an in-
verse correlation between the incidence of colon cancer
and the use of nonsteroidal anti-inflammatory drugs
(NSAIDs), which inhibit prostaglandin synthesis [8]. Be-
cause COX-2 is frequently over-expressed in premalignant
lesions and neoplasms, specific COX-2 inhibitors have
been investigated as chemo-preventive and potential
chemotherapeutic agents [6–8]. New preclinical and early
clinical data suggest, that inhibitors of COX-2 may protect
against colon, breast, lung, esophageal, and oral tumors
[8]. Even though epidemiological studies on the role of
NSAIDs in pancreatic cancer incidence are not as detailed
as in colonic cancer, evidence does suggest that NSAIDs
might decrease the incidence of pancreatic cancer [34]. Re-
cently, Anderson and colleagues [34] from University of
Minnesota investigated the association between pancreat-
ic cancer and aspirin and other nonsteroidal anti-inflam-
matory drugs (NSAIDs) in 28283 participants.
Multivariate analysis suggested that women who used as-
pirin had a 43% lower risk of pancreatic cancer compared
with those who did not use aspirin. Furthermore, the as-
sociation appeared to be related to the dose; women who
took aspirin 2–5 times a week had a 53% lower risk, and
those who took aspirin six or more times a week had a
60% lower risk than women who never took aspirin. In
contrast to COX inhibitors, epidemiological evidence re-
garding the effect of LOX inhibitors on pancreatic cancer
incidence is lacking, since specific LOX inhibitors have
only recently become available in the clinic.
Expression of COX and LOX in pancreatic cancer
COX-2 is only expressed in pancreatic islets and has no ex-
pression in normal exocrine pancreatic tissues [35]. A con-
siderable amount of evidence from several clinical studies
in the United States and Japan supports that COX-2 is up-
regulated in pancreatic adenocarcinoma. Studies that
demonstrate this have employed RT-PCR, quantitative RT-
PCR, in situ hybridization, western blotting and immuno-
histochemistry [36–42]. One report showed that levels of
COX-2 mRNA were more than 60-fold increased in pan-
creatic cancer compared to adjacent non-tumor tissue
[36]. The COX-2 protein was detected in 90% of pancreat-
ic adenocarcinomas [36]. In general, studies suggest that
COX-2 is weakly expressed in benign pancreatic adenoma,
but dramatically up-regulated in pancreatic adenocarcino-
ma, even though extent of COX-2 expression differs from
one study to another [36–42]. Expression of COX-2 has
been demonstrated in several pancreatic cancer cell lines,
although once again there is a lack of consistency between
different studies [38,43]. Nzeako and Gores, analyzed
possible reasons for the inconsistent reporting of COX-2
expression by different groups [44]. Firstly, the lack of cor-
relation in immunohistochemical staining intensity for
COX-2 may result from working with previously fixed and
embedded tissue, the fixation methods used and the dura-
tion of fixation. The process of fixing and embedding can
destroy or denature cellular proteins, thereby altering an-
tigenic recognition by immunohistochemistry [44]. Un-
der such circumstances, attempts at correlating staining
intensity with other variables are very likely to yield spuri-
ous results. In this situation, more reliable results may be
obtained using frozen tissues with a standardized fixation
procedure. Secondly, the use of polyclonal antibodies for
immunohistochemistry may diminish reliability, since
other tissue proteins may be inadvertently stained [44].Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/10
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Despite these inconsistencies, all of these studies indicate
that COX-2 is over-expressed in pancreatic cancer. A re-
cent study showed, that perineural invasion was associat-
ed with COX-2 expression in pancreatic cancer and
increased COX-2 expression was more common in the
glandular component than the solid component of the tu-
mors [41]. Regarding expression of COX-2 in early neo-
plastic lesions of the pancreas, researchers from John
Hopkins immunohistochemically examined expression
of COX-2 in adenocarcinomas, pancreatic intraepithelial
neoplasia [PanIN] and normal pancreatic ducts with an
automated platform [42]. The overall percentage of posi-
tive cells was 47.3% in adenocarcinomas, 36.3% in
PanINs and 19.2% in normal ducts. COX-2 was expressed
in more than 20% of cells in 23 adenocarcinomas (77%),
42 PanINs (65%), and 12 normal ducts (40%). Signifi-
cant differences in COX-2 expression were demonstrable
in both adenocarcinomas vs normal ducts and PanINs vs
normal ducts [42]. The up-regulation of COX-2 in a subset
of noninvasive precursor lesions makes it a potential tar-
get for chemoprevention using selective COX-2 inhibi-
tors.
Expression of LOX is also up-regulated in both adenocar-
cinomas and early neoplastic lesions of the pancreas. Re-
verse transcriptase-polymerase chain reaction revealed
expression of 5-LOX mRNA in all of the commonly used
pancreatic cancer cell lines, including PANC-1, AsPC-1,
and MiaPaCa2 cells, but not in normal pancreatic ductal
cells [45]. The expression of the 5-LOX protein in pancre-
atic cancer cell lines was confirmed by western blotting
[46]. 5-LOX up-regulation in human pancreatic cancer tis-
sues was verified by immunohistochemistry, which re-
vealed intense positive staining in cancer cells [46].
Staining of the 5-LOX protein was particularly evident in
the ductal components of the more differentiated tumors
but, in contrast, ductal cells in normal pancreatic tissues
from organ donors did not stain. Immunohistochemistry
also revealed strong staining of cancer tissues with an an-
tibody to the receptor of the downstream 5-LOX metabo-
lite, leukotriene B4 [46]. It also appears that levels of 5-
LOX in hepatic metastases of pancreatic cancer express
more 5-LOX than the primary tumors [46]. These findings
provide further evidence of up-regulation of this pathway
in pancreatic cancer and suggest that LOX inhibitors are
likely to be valuable for the treatment or prevention of
this dreadful disease.
There is also RT-PCR evidence of 12-LOX expression in
pancreatic cancer cell lines [45]. Expression of 12-LOX in
pancreatic islets has been reported and it is not yet clear,
whether 12-LOX is expressed or up-regulated in pancreat-
ic cancer [47]. Whether 15-LOX and 8-LOX are expressed
in pancreatic cancer or in normal pancreatic tissues has
not been investigated.
Effects of COX and LOX inhibition on pancreatic cancer 
growth and apoptosis: In vitro and in vivo studies
The effects of COX inhibition on pancreatic cancer growth
has been examined both in vitro and in vivo, using both
non-specific NSAIDs and specific COX-2 inhibitors. The
effect of these inhibitors depends, at least in part, on the
COX-2 pathway in cultured pancreatic cancer cell lines
[48]. One study showed that COX inhibitors significantly
suppressed proliferation of cells that have high levels of
COX-2 expression, but exerted minimal effects on prolif-
eration in cells with a significantly lower level of COX-2
[48]. We have reported that the non-specific COX inhibi-
tor, indomethacin is equally potent in inhibiting pancre-
atic cancer cell proliferation compared with the specific
COX-2 inhibitor, NS398 [43].
Another important action of the COX-2 enzyme is inhibi-
tion of apoptosis, which in many cases constitutes anoth-
er mechanism to promote tumor cell growth. Several
studies have revealed that COX-2-specific and non-specif-
ic NSAIDs induce apoptosis in a variety of cancer cells, in-
cluding colon, gastric, glioma, and lung cancer cells [6–8].
Recently, we and others have demonstrated that COX in-
hibitors significantly induce apoptosis in pancreatic can-
cer cells [43]. Non-specific NSAIDs and COX-2 specific
inhibitors were also equipotent for inducing apoptosis,
suggesting that the COX-2 pathway plays a key role in pre-
venting apoptosis and that NSAIDs reverse this effect by
inhibiting the pathway [43]. Pancreatic cancer growth is
inhibited by COX-2 in animal models as well as in vitro.
Our data show that the COX-2 inhibitor, celecoxib signif-
icantly decreases both volume and weight of pancreatic
tumors xenografted subcutaneously into nude mice.
Compared with the investigations on the role of COX in
the development and growth of cancers, information re-
garding the role of lipoxygenases in the regulation of pan-
creatic cancer growth is limited. Studies conducted by
Anderson et al showed inhibition of pancreatic cancer cell
proliferation following treatment with the 5-lipoxygenase
activating protein (FLAP) inhibitor, MK886 [49–51]. Co-
incident with growth inhibition, changes in expression of
several genes, including tumor suppressor genes and
growth factor receptors were induced by MK886 [50]. An-
derson et al reported that MK886 induces an "atypical" ap-
optosis in PANC-1 pancreatic cancer cells which is
enhanced by gamma linolenic acid [51]. We recently ex-
plored the effect of LOX inhibition on pancreatic cancer
cell proliferation and survival using pharmacological LOX
inhibitors and a FLAP inhibitor, as well as antisense oligo-
nucleotides targeting 5-LOX, 12-LOX or 15-LOX expres-
sion [45,52]. Blockade of either 5-LOX or 12-LOX
markedly inhibited cell proliferation and induced apopto-
sis in all of the pancreatic cancer cell lines studied. Apop-
tosis induced by blockade of either the 5-LOX or 12-LOXMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/10
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enzyme was documented by propidium iodide DNA
staining, demonstration of DNA fragmentation by elec-
trophoresis as well as by the TUNEL assay [45,52]. Anti-
sense oligonucleotides directed against both 5-LOX and
12-LOX had similar inhibitory effects on pancreatic cancer
cell proliferation to the small drug LOX inhibitors. In con-
trast, 15-LOX does not appear to play any important role
in pancreatic cancer cell growth, since transfection of 15-
LOX antisense oligonucleotide did not affect DNA synthe-
sis of pancreatic cancer cells in our studies [45]. These
studies support the potential use of LOX inhibitors in
pancreatic cancer treatment or prevention. Animal experi-
ments conducted in our laboratory indicate that blockade
of LOX pathways also inhibits growth of pancreatic can-
cers xenografted into athymic nude mice [53,54]. While
the study conducted by Anderson et al showed that block-
ade of 5-LOX induced only an "atypical" apoptosis, our
data clearly show that apoptosis is induced by LOX en-
zyme inhibition [52]. The reasons for these different re-
sults are not clear. To confirm that apoptosis occurs in
pancreatic cancer cells following LOX inhibitor treatment,
we conducted further studies that showed that LOX inhib-
itors reduce expression of Bcl-2 and Mcl-1 and induce ac-
tivation of caspase-3 and -9 as well as cleavage of the
caspase-3 target, PARP [53,54].
Prevention of pancreatic cancer with COX and LOX inhib-
itors
Pancreatic carcinoma can be induced in hamster models
by administering N-nitrosobis(2-oxopropyl)amine
(BOP). This animal model mimics human pancreatic can-
cer biologically and genetically, including mutated k-Ras,
desmoplasia and insulin resistance [55–57]. Takahashi et
al treated hamsters with BOP and then subsequently treat-
ed them with the non-selective COX inhibitors, in-
domethacin or aspirin [58]. Animals in the indomethacin
group developed significantly fewer tumors than the con-
trol group. Aspirin also had a tendency to decrease the in-
cidence of pancreatic cancers [58]. Using the same
pancreatic cancer model, Wenger et al reported that the
specific COX-2 inhibitor, celebrex also prevented pancre-
atic cancer [59].
Several excellent studies support the use of COX inhibi-
tors for preventing cancer of different organs including co-
lon, lung, breast and pancreas, while exploration of the
potential for LOX inhibitors as chemopreventive agents is
just beginning. It was recently reported that 5-LOX path-
way inhibitors, accolate, MK-886, zileuton, and combina-
tions of zileuton with either accolate or MK-886 reduced
lung tumor multiplicity by 37.8, 29.5, and 28.1%, respec-
tively following injection of lung cancer carcinogen vinyl
carbamate into mice [60]. These inhibitors also decreased
the size of the tumors and the yield of carcinomas [60]. An
extract from the sea cucumber, Cucumaria frondosa which
is a potent LOX inhibitor, attenuates pancreatic cancer de-
velopment. In our recent study, hamsters were fed with an
extract of sea cucumber for one week before pancreatic
cancer cells were transplanted orthotopically into the pan-
creas. The extract decreased pancreatic cancer incidence as
well as tumor size.
Molecular mechanisms of COX and LOX-medi-
ated pancreatic cancer development
Mitogenic effects of COX and LOX metabolites
Evidence suggests that the prostaglandin products of the
COX pathway, especially PGE2 enhance cell proliferation
in either normal and cancer cells through specific recep-
tors [61–67]. Prostaglandins exert their effects locally in
both an autocrine and paracrine manner. PGE2 receptors
are a family of G-protein-coupled receptors, namely, EP1,
EP2, EP3, and EP4 [68]. Functional studies on the EP re-
ceptors have relied on use of EP knockout mice. The defi-
ciency of the prostaglandin receptor EP2 gene reduced the
size and number of intestinal tumors in APC716 mice,
similar to deficiency of the COX-2 gene [69]. Besides pros-
taglandin E2 and its receptor, thromboxane A2 is also in-
volved in cancer development [70–75]. Thromboxane A2
enhances cancer cell proliferation, while its antagonist
blocks cancer cell growth. We have shown that both 5-
LOX and 12-LOX are also involved in pancreatic cancer
cell proliferation. Both 5-HETE and 12-HETE enhance
DNA synthesis in pancreatic cancer cells by activating
multiple intracellular signal pathways [76–78]. Our most
recent study suggests that LTB4 receptors are up-regulated
in human pancreatic cancer tissues and coincidentally,
pancreatic cancer cells produce LTB4 [46]. This autocrine
loop might be important for pancreatic cancer cell
growth, as LTB4 itself stimulates pancreatic cancer cell
growth while the LTB4 receptor antagonist, LY293111
blocks growth of pancreatic cancer both in vitro and in vivo
[79]. The signaling pathways that respond to COX and
LOX-derived metabolites in cancer cells include ERK1/2,
PI3 kinase/AKT cascade, tyrosine kinases, STAT, c-Myc and
others which are summarized in Table 1.
Regulation of cell survival by COX and LOX
Inhibition of either COX or LOX induces apoptosis of
pancreatic cancer cells while forced expression of COX-2
prevents apoptosis. Multiple cellular proteins are involved
in this process and mitochondria are the key organelles
for COX or LOX inhibition-induced apoptosis [83–86].
Treatment of cancer cells with COX inhibitors induces cy-
tochrome C release from mitochondria, which in turn ac-
tivates caspase-9 and then caspase-3 [83–86].
Cytochrome C release seems to be directly related to COX
inhibition since addition of prostaglandin E2 can prevent
NS398-induced cytochrome C release, caspase activation
and PARP cleavage [83–86]. Other studies have shownMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/10
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that over-expression of COX-2 increases Bcl-2 expression,
which might be responsible for preventing cytochrome C
release from mitochondria [87]. A recent study showed
that death receptors are also involved in COX-regulated
cancer cell survival [88–90]. Forced COX-2 expression sig-
nificantly attenuated TRAIL-induced apoptosis and was
associated with transcriptional repression of death recep-
tor-5 and up-regulation of Bcl-2 [89]. Over-expression of
COX-2 also reduced caspase-8, caspase-3, and caspase-9
activation relative to corresponding parental cells [89]. In
contrast, COX inhibitors were able to restore death recep-
tor-5 expression. Several lines of evidence suggests that
NFκB and PI3 kinase are involved in NSAID-induced can-
cer cell apoptosis [89]. NSAIDs inhibit NFκB and PI3 ki-
nase activity, while restoration of NFκB or PI3 kinase
activity blocks NSAID-induced apoptosis [91–93]. Inhibi-
tion of COX-2 causes an increase in tissue concentrations
of ceramide. Since ceramide is an effective inducer of ap-
optosis, metabolism of arachidonic acid by COX-2 might
prevent apoptosis by reducing intracellular ceramide con-
centrations. Therefore, an imbalance between PGE2 and
ceramide may contribute to the apoptosis-preventing ef-
fects of COX-2 in cancer cells [94,95]. The mechanisms in-
volved in COX-mediated cancer cell survival are complex
and it is likely that even more pathways involved in these
effects will be identified in the future.
To date, three signal cascades have been shown to be
linked to LOX-regulated pancreatic cancer cell survival.
The first pathway is the Bcl protein family-release of cyto-
chrome C from mitochondria-caspase cascade [53,54,96–
98]. Treatment of pancreatic cancer cells with either 5-
LOX or 12-LOX inhibitors, dramatically upsets the bal-
ance between the anti-apoptotic proteins (such as Bcl-2,
Mcl-1) and the pro-apoptotic protein (Bax). This in-
creased pro/anti-apoptotic protein ratio triggers cyto-
chrome C release from mitochondria, which in turn
activates caspase cascade and results in apoptosis. The sec-
ond cascade is the extracellular regulated kinase cascade
(MEK/ERK). It is known that activation of the MEK/ERK
signal transduction pathway prevents apoptosis. Our
studies show that the LOX metabolites, 5-HETE, 12-HETE
and LTB4 stimulate MEK/ERK phosphorylation [76–
78,80]. PI3 kinase/AKT protects cells from apoptosis by
phosphorylation of Bad. Bad is a pro-apoptotic member
of the Bcl-2 family that can displace Bax from binding to
Bcl-2 and Bcl-xL, resulting in cell death. Phosphorylation
of Bad results in its binding to 14-3-3 proteins and pre-
vents it binding to Bcl-2 and Bcl-xL. We have shown that
both 5-HETE and LTB4 activate the PI3 kinase/AKT cas-
cade, which constitutes the third pathway which links
LOX activation to the prevention of apoptosis in pancre-
atic cancer cells [78–80].
Modulation of cell migration, invasion and angiogenesis
It is well documented that COX inhibitors reduce cancer
cell migration, cell adhesion and tumor invasiveness
[6,7,99]. In contrast, constitutive COX-2 expression leads
to enhanced cell invasiveness [100,101]. The biochemical
changes associated with over-expression of COX-2 in-
clude increased expression and activation of metallopro-
teinase-2 (MMP-2) and reduced expression of E-cadherin
[102–104]. We speculate that there are likely to be several
pathways that mediate COX-2-promoted cell invasion,
which may be cell-type dependent. The multiple effects of
COX-2 on cell motility and cell adhesion suggest a key
role for COX-2 in tumor invasiveness and angiogenesis.
Both non-specific and specific COX-2 inhibitors signifi-
cantly inhibit angiogenesis, a process that involves inacti-
Table 1: Signal molecules activated or upregulated by COX and LOX metabolites
Metaboltes Activated Molecules References
13-HODE PKCα Liu et al, 1995
12-HETE PKCα Liu et al, 1997
12-HETE c-Src Szekeres et al, 2000
12-HETE PI3 kinase Szekeres et al, 2000
5-HETE PI3 kinase Ding et al, 2001
5-HETE tyrosine kinase Ding et al, 2001
5-HETE/12-HETE P38 kinase Ding et al, 2001
PGE2 VEGF Pai et al, 2001
12-HETE ERK1/2 Ding et al, 2001
PGE2/EP3 receptor Ras/MEK/ERK Yano et al, 2002
PGE2 EGF receptor Pai et al, 2002
PGE2/EP4 IL-6 release Fiebich et al, 2001
PGE2/EP2/EP4 PI3 kinase/GSK Fujino et al, 2002
PGE2 STAT Liu et al, 2002
LTB4 ERK1/2 Tong et al, 2002Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/10
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vation of the MAPK pathway. COX-2 induces the
production of vascular endothelial growth factor (VEGF),
a proangiogenic growth factor. This induction is blocked
by a COX-2 specific inhibitor, NS-398 [105–107]. Recent-
ly, the molecular mechanism for COX-2-mediated VEGF
expression has been elucidated. A large amount of PGE2 is
generated when COX-2 expression is induced or over-ex-
pressed in pancreatic cancer. Activation of the PGE2 sur-
face membrane receptors increases intracellular cAMP, in
turn stimulating VEGF production and thereby promoting
neovascularization and tumor angiogenesis [108]. Sepa-
rate studies suggest that other products of the COX path-
way, thromboxane A2  and PGI2  also promote
angiogenesis [72,75,109,110]. The thromboxane A2 ana-
logue, U46619, stimulates endothelial cell migration
[72]. On the other hand, basic fibroblast growth factor
(bFGF) or vascular endothelial growth factor (VEGF),
which are angiogenic, increase thromboxane A2 synthesis
[111–113]. In contrast, inhibition of thromboxane A2
synthesis reduces HUVEC migration stimulated by VEGF
or bFGF [75,114]. Furthermore, the thromboxane A2 re-
ceptor antagonist inhibits VEGF- or bFGF-stimulated en-
dothelial cell migration and bFGF-induced angiogenesis
in vivo [75,114].
LOX activity is required for serum- and bFGF-stimulated
endothelial cell proliferation and for modified low-densi-
ty lipoprotein-induced monocyte binding to endothelial
cells [115]. 12(S)-HETE can directly stimulate endothelial
cell mitogenesis, migration and surface expression of in-
tegrin [115–118]. In addition to its role in endothelial cell
migration, 12-LOX is also involved in endothelial cell dif-
ferentiation, seen as tube formation [115]. Pretreatment
of endothelial cells with the 12-LOX inhibitor, BHPP in-
hibits the formation of these vessel-like structures in
Matrigel. Exogenous 12(S)-HETE can induce a reversible
retraction of endothelial cell monolayers cultured on col-
lagen by regulating PKC [115–118]. The involvement of
12-LOX in endothelial cell angiogenic responses seen in
vitro has been confirmed in vivo, by the observation that
the 12-LOX inhibitor, BHPP significantly reduces bFGF-
stimulated angiogenesis [115]. The role of 12-LOX in en-
dothelial cell proliferation, together with the finding that
12-LOX is involved in endothelial cell migration and dif-
ferentiation, implicate the mobilization of arachidonic
acid and the generation of 12(S)-HETE in endothelial cells
as an early event in the intracellular cascade of angiogenic
responses. We have reported that levels of 5-LOX in met-
astatic pancreatic cancer are higher than in non-metastatic
tumor. However, there is little information on the role of
5-LOX on the regulation of angiogenesis and cancer me-
tastasis.
Immune suppression
Individuals at high risk for pancreatic cancer include
smokers, and persons with all forms of chronic alcoholic,
metabolic, tropical or hereditary pancreatitis. The dura-
tion of exposure to inflammation seems to be the major
factor involved in the transition from benign to malignant
condition [119–122]. Cytokine-mediated up-regulation
of COX-2 contributes to increased synthesis of PGs in in-
flamed tissues [119–122]. The occurrence and growth of
various tumors are associated with immune suppression
and prostaglandin E2 itself is a potent immunsuppressor
[119–121]. Not only do cancer cells themselves produce
prostaglandins, but factors released from tumor cells acti-
vate monocytes and macrophages to synthesize PGE2. In
turn, PGE2 inhibits the production of immune regulatory
lymphokines, T-cell and B-cell proliferation, and the cyto-
toxic activity of natural killer cells, thus favoring tumor
growth [119–121]. PGE2 also inhibits the production of
tumor necrosis factor-α and induces the production of IL-
10, an immunosuppressive cytokine [119–123]. Recently,
more molecular mechanisms for PGE2-mediated immu-
nosuppression have been revealed. For example, PGE2
suppressed IL-15-mediated human natural killer cell func-
tion [123].
Free radicals and peroxidation
Nitric oxide (NO) is a short-lived molecule required for
many physiological functions which is produced from L-
arginine by NO synthases (NOS) [124]. It is a free radical,
producing many reactive intermediates that account for its
bioactivity [124]. Sustained induction of the inducible
form of NOS (iNOS) in chronic inflammation may be
mutagenic, either through NO-mediated DNA damage or
by hindering DNA repair. Thus sustained NO production
is potentially carcinogenic [124]. Progression of the ma-
jority of human and experimental tumors appears to be
stimulated by NO resulting from activation of iNOS or
constitutive NOS [124]. NO can stimulate tumor growth
and metastasis by promoting migration and invasion,
which may also be triggered by activation of cyclooxygen-
ase [125,126]. Furthermore, iNOS is induced by COX-2
and there is a significant correlation between positive
COX-2 and iNOS expression in cancer tissues [125,126].
Both COX and LOX enzymes are peroxidases. It has been
proposed that the peroxidase activity of these enzymes
may catalyze the conversion of procarcinogens into car-
cinogens [127–134]. In the liver, such oxidative reactions
are catalyzed principally by cytochrome P-450s. However,
pancreatic tissues and other organs frequently have low
concentrations of P-450s and, therefore, significant
amounts of xenobiotics may be co-oxidized to mutagens
by the peroxidase activities of COX and LOX [126]. In ad-
dition to catalyzing the synthesis of mutagens, both COX-
2 and LOX can be induced by carcinogens, such as NNKMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/10
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and BOP [131–134]. Our unpublished data show that
both 5-LOX and 12-LOX are induced in pancreatic ductal
cells following treatment with BOP or NNK. Other studies
showed that carcinogens induce COX-2 expression and
COX-2 in turn catalyzes the oxidation of procarcinogens
to produce a highly reactive and strongly mutagenic com-
pounds [132,127,133]. Taken together, these findings
suggest a role for COX-2 or LOX inhibitors in preventing
carcinogen-induced DNA damage, thereby preventing
cancer development.
Feasibility of targeting cyclooxygenase and 
lipoxygenase for treatment and prevention of 
pancreatic cancer
The requirements for a chemopreventive drug are that it
must have specific targets that are highly expressed in pre-
cancer or cancer cells. Such an agent should not be toxic
and not disrupt normal cellular functions. Both COX-2
and LOX are up-regulated in cancer and genetic knockouts
of these targets do not appear to disrupt normal functions
of mice, although there is loss of inflammatory function.
These enzymes should, therefore, be ideal targets for pan-
creatic cancer treatment and chemoprevention. Indeed,
COX-2 inhibitors are already being used clinically for co-
lon cancer prevention. Molecular studies indicate that car-
cinogenesis is a multistep (accumulated genetic and
epigenetic alterations), multipath (multiple functional
pathways) and multifocal process, frequently driven by
genetic instability. Therefore, a combination of drugs with
different targets is likely to enhance the efficiency of can-
cer treatment and chemoprevention. We believe that a
combination of COX and LOX inhibitors will yield better
results in pancreatic cancer treatment and prevention. Al-
though this approach needs to be confirmed in future
studies. Development of drugs targeting both enzymes
would be another useful future direction for cancer treat-
ment and prevention.
Several compounds that have either anti-COX or anti-LOX
activities have been identified from natural products or
food supplements. For example, a polyphenol isolated
from the skins of grapes, resveratrol has been shown to be
a potent anti-pancreatic cancer agent and is also a COX in-
hibitor [135]. Ajoene, a garlic-derived natural product
that interfaces with the COX-2 enzyme, has anti-cancer ac-
tivities [136,137]. Other anti-COX-2 agents extracted
from green tea and certain herbal medicines also have ef-
fects on cancer development [138,139]. Recently, we
found that a polar lipid isolate from sea cucumbers mark-
edly blocks pancreatic cancer cell proliferation and induc-
es apoptosis. The anti-pancreatic cancer activity of this
extract is probably mediated through inhibition of LOX
activity, since it inhibits LTB4 secretion. Furthermore,
adding LOX metabolites blocks the inhibitory effect of
this extract on pancreatic cancer cell proliferation. These
natural products are likely to be valuable in preventing
pancreatic cancer development if we could identify high
risk pancreatic cancer populations, since these natural
products are available in the food chain.
There are, of course, certain problems which need to be
solved before the use of COX and LOX enzyme inhibitors
can be translated into the clinic for pancreatic cancer treat-
ment and prevention. The specificity of drugs is an impor-
tant issue facing clinicians [140]. Even though it is
claimed that celecoxib and other compounds are specific
COX-2 inhibitors, the interpretation of COX-2 studies is
complicated by possible COX-2-independent mecha-
nisms [140]. In some cases, NSAIDs only induce apopto-
sis at concentrations that are much higher than their IC50s
[140]. In addition, NSAIDs have been shown to trigger ap-
optosis in COX-2 deficient cells and NSAID metabolites
that do not inhibit COX, such as sulindac sulfone, can
also cause apoptosis by inhibiting cGMP-dependent
phosphodiesterase [140]. Therefore, the cancer inhibitory
effects of COX-2 inhibitors seem to involve COX-2 inde-
pendent mechanisms [140]. With regard to LOX inhibi-
tors, none of these have yet reached the clinic for testing
of anti-cancer activity.
There still is debate about the specific role of COX-2 in
cancer development. It is indeed that COX-2 over-expres-
sion increases tumor growth and that the COX-2 protein
is strongly induced in cancer cells. However, COX-1 may
have an important role in cancer prevention as suggested
by the COX-1-deficient Min mice. When Min mice were
treated with celecoxib or the conventional NSAID piroxi-
cam, the number of tumors per animal was significantly
reduced. Knocking out the COX-2 gene resulted in an 8-
fold reduction in the intestinal tumor burden. However,
COX-1-deficient Min mice exhibit similar decreases in in-
testinal tumorigenesis as COX-2-null Min mice [12]. The
recent finding of an inducible splicing variant of COX-1
(COX-3) can only further complicate the current contro-
versy.
Further work is needed to target LOX enzymes chemopre-
vention, including the validation of these targets and the
establishment of useful LOX modulators. It is important
to clarify the mechanism by which LOX inhibition affects
cell proliferation and apoptosis. The roles of 15-LOX and
8-LOX in pancreatic cancer development and growth still
need to be clarified. Further studies may reveal new LOXs
and new roles for known LOXs in the development and
reversal of cancer and this will also help us to define a spe-
cific and effective LOX inhibitor for preventing pancreatic
cancer.Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/10
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Conclusion
COX and LOX metabolism of linoleic and arachidonic ac-
ids leads to the formation of a variety of metabolically ac-
tive products with different roles in carcinogenesis. Our
understanding of these roles is steadily increasing. This
new information is providing a theoretical basis for devel-
opment of new cancer chemoprevention approaches tar-
geted to COX and LOX activity. Since no effective
treatment is currently available for pancreatic cancer,
blockade of the COX and LOX pathways might be valua-
ble in the future for treating and preventing this dreadful
disease.
Authors' contributions
Xian-Zhong Ding conducted the literature reviews and
drafted this article. Rene Hennig and Thomas E. Adrian
provided suggestions and edited the manuscript. All au-
thors read and approved the content of the final manu-
script.
Acknowledgments
Supported by grants from the NCI SPORE program (P50 CA72712), the 
Lustgarten Foundation for Pancreatic Cancer Research (LF49), and the 
American Institute for Cancer Research (00B065).
References
1. Lipkin M, Reddy B, Newmark H and Lamprecht SA Dietary factors
in human colorectal cancer. Annu Rev Nutr 1999, 19:545-586
2. Willett WC Specific fatty acids and risks of breast and pros-
tate cancer: dietary intake.  Am J Clin Nutr 1997, 66(6 Sup-
pl):1557S-1563S
3. Klurfeld DM and Bull AW Fatty acids and colon cancer in exper-
imental models. Am J Clin Nutr 1997, 66(6 Suppl):1530S-1538S
4. Guthrie N and Carroll KK Specific versus non-specific effects of
dietary fat on carcinogenesis. Prog Lipid Res 1999, 38:261-271
5. Funk CD Prostaglandins and leukotrienes: advances in eicosa-
noid biology. Science 2001, 294(5548):1871-1875
6. Cao Y and Prescott SM Many actions of cyclooxygenase-2 in cel-
lular dynamics and in cancer. J Cell Physiol 2002, 190:279-286
7. Lin DT, Subbaramaiah K, Shah JP, Dannenberg AJ and Boyle JO Cy-
clooxygenase-2: A novel molecular target for the prevention
and treatment of head and neck cancer.  Head Neck 2002,
24:792-799
8. Howe LR and Dannenberg AJ A role for cyclooxygenase-2 inhib-
itors in the prevention and treatment of cancer. Semin Oncol
2002, 29(3 Suppl 11):111-119
9. Ding XZ, Tong WG and Adrian TE Cyclooxygenases and lipoxy-
genases as potential targets for treatment of pancreatic can-
cer. Pancreatology 2001, 1(4):91-99
10. Dannenberg AJ, Altorki NK, Boyle JO, Dang C, Howe LR, Weksler
BB and Subbaramaiah K Cyclo-oxygenase 2: a pharmacological
target for the prevention of cancer. Lancet Oncol 2001, 2:544-
551
11. Gupta RA and Dubois RN Colorectal cancer prevention and
treatment by inhibition of cyclooxygenase-2. Nat Rev Cancer
2001, 1:11-21
12. Williams CS, Mann M and DuBois RN The role of cyclooxygenas-
es in inflammation, cancer, and development. Oncogene 1999,
18:7908-7916
13. Chandrasekharan NV, Dai H, Roos KL, Evanson NK, Tomsik J, Elton
TS and Simmons DL From the Cover: COX-3, a cyclooxygen-
ase-1 variant inhibited by acetaminophen and other analge-
sic/antipyretic drugs: Cloning, structure, and expression.
PNAS 2002, 99:13926-13931
14. Iversen L and Kragballe K Arachidonic acid metabolism in skin
health and disease. Prostaglandins Other Lipid Mediat 2000, 63:25-42
15. Yamamoto S, Suzuki H, Nakamura M and Ishimura K Arachidonate
12-lipoxygenase isozymes. Adv Exp Med Biol 1999, 447:37-44
16. Brash AR, Jisaka M, Boeglin WE and Chang MS Molecular cloning
of a second human 15S-lipoxygenase and its murine homo-
logue, an 8S-lipoxygenase. Their relationship to other mam-
malian lipoxygenases. Adv Exp Med Biol 1999, 447:29-36
17. Kuhn H and Borngraber S Mammalian 15-lipoxygenases. Enzy-
matic properties and biological implications. Adv Exp Med Biol
1999, 447:5-28
18. Steele VE, Holmes CA, Hawk ET, Kopelovich L, Lubet RA, Crowell
JA, Sigman CC and Kelloff GJ Lipoxygenase inhibitors as poten-
tial cancer chemopreventives. Cancer Epidemiol Biomarkers Prev
1999, 8:467-83
19. Gunning WT, Kramer PM, Steele VE and Pereira MA Chemopre-
vention by lipoxygenase and leukotriene pathway inhibitors
of vinyl carbamate-induced lung tumors in mice. Cancer Res
2002, 62:4199-4201
20. Ghosh J and Myers CE Central role of arachidonate 5-lipoxyge-
nase in the regulation of cell growth and apoptosis in human
prostate cancer cells. Adv Exp Med Biol 1999, 469:577-82
21. Anderson KM, Seed T, Jajeh A, Dudeja P, Byun T, Meng J, Ou D,
Bonomi P and Harris JE An in vivo inhibitor of 5-lipoxygenase,
MK886, at micromolar concentration induces apoptosis in
U937 and CML cells. Anticancer Res 1996, 16(5A):2589-99
22. Tang DG and Honn KV Apoptosis of W256 carcinosarcoma
cells of the monocytoid origin induced by NDGA involves li-
pid peroxidation and depletion of GSH: role of 12-lipoxygen-
ase in regulating tumor cell survival.  J Cell Physiol 1997,
172(2):155-70
23. Nie D, Che M, Grignon D, Tang K and Honn KV Role of eicosa-
noids in prostate cancer progression.  Cancer Metastasis Rev
2001, 20:195-206
24. Brash AR, Jisaka M, Boeglin WE and Chang MS Molecular cloning
of a second human 15S-lipoxygenase and its murine homo-
logue, an 8S-lipoxygenase. Their relationship to other mam-
malian lipoxygenases. Adv Exp Med Biol 1999, 447:29-36
25. Iversen L and Kragballe K Arachidonic acid metabolism in skin
health and disease. Prostaglandins Other Lipid Mediat 2000, 63:25-42
26. Muga SJ, Thuillier P, Pavone A, Rundhaug JE, Boeglin WE, Jisaka M,
Brash AR and Fischer SM 8S-lipoxygenase products activate
peroxisome proliferator-activated receptor alpha and in-
duce differentiation in murine keratinocytes. Cell Growth Differ
2000, 11(8):447-54
27. Burger F, Krieg P, Kinzig A, Schurich B, Marks F and Furstenberger G
Constitutive expression of 8-lipoxygenase in papillomas and
clastogenic effects of lipoxygenase-derived arachidonic acid
metabolites in keratinocytes. Mol Carcinog 1999, 24:108-17
28. Shureiqi I and Lippman SM Lipoxygenase modulation to reverse
carcinogenesis. Cancer Res 2001, 61:6307-12
29. Eling TE and Glasgow WC Cellular proliferation and lipid me-
tabolism: importance of lipoxygenases in modulating epider-
mal growth factor-dependent mitogenesis. Cancer Metastasis
Rev 1994, 13:397-410
30. Eling TE, Everhart AL, Angerman-Stewart J, Hui R and Glasgow WC
Modulation of epidermal growth factor signal transduction
by linoleic acid metabolites. Adv Exp Med Biol 1997, 407:319-22
31. Shureiqi I, Chen D, Lotan R, Yang P, Newman RA, Fischer SM and
Lippman SM 15-Lipoxygenase-1 mediates nonsteroidal anti-in-
flammatory drug-induced apoptosis independently of cy-
clooxygenase-2 in colon cancer cells. Cancer Res 2000, 60:6846-
50
32. Profita M, Sala A, Siena L, Henson PM, Murphy RC, Paterno A, Bon-
anno A, Riccobono L, Mirabella A, Bonsignore G and Vignola AM
Leukotriene B4 production in human mononuclear phago-
cytes is modulated by interleukin-4-induced 15-lipoxygen-
ase. J Pharmacol Exp Ther 2002, 300:868-75
33. Shappell SB, Gupta RA, Manning S, Whitehead R, Boeglin WE, Schnei-
der C, Case T, Price J, Jack GS, Wheeler TM, Matusik RJ, Brash AR
and Dubois RN 15S-Hydroxyeicosatetraenoic acid activates
peroxisome proliferator-activated receptor gamma and in-
hibits proliferation in PC3 prostate carcinoma cells. Cancer
Res 2001, 61:497-503
34. Anderson KE, Johnson TW, Lazovich D and Folsom AR Association
between nonsteroidal anti-inflammatory drug use and the
incidence of pancreatic cancer. J Natl Cancer Inst 2002, 94:1168-
71Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/10
Page 10 of 12
(page number not for citation purposes)
35. O'Neill GP and Ford-Hutchinson AW Expression of mRNA for
cyclooxygenase-1 and cyclooxygenase-2 in human tissues.
FEBS Lett 1993, 330:156-60
36. Tucker ON, Dannenberg AJ, Yang EK, Zhang F, Teng L, Daly JM,
Soslow RA, Masferrer JL, Woerner BM, Koki AT and Fahey TJ 3rd
Cyclooxygenase-2 expression is up-regulated in human pan-
creatic cancer. Cancer Res 1999, 59:987-90
37. Okami J, Yamamoto H, Fujiwara Y, Tsujie M, Kondo M, Noura S, Os-
hima S, Nagano H, Dono K, Umeshita K, Ishikawa O, Sakon M, Mats-
uura N, Nakamori S and Monden M Overexpression of
cyclooxygenase-2 in carcinoma of the pancreas. Clin Cancer Res
1999, 5:2018-24
38. Molina MA, Sitja-Arnau M, Lemoine MG, Frazier ML and Sinicrope FA
Increased cyclooxygenase-2 expression in human pancreatic
carcinomas and cell lines: growth inhibition by nonsteroidal
anti-inflammatory drugs. Cancer Res 1999, 59(17):4356-4362
39. Yip-Schneider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin
A, Marshall SJ, Crowell PL, Marshall MS and Sweeney CJ Cyclooxy-
genase-2 expression in human pancreatic adenocarcinomas.
Carcinogenesis 2000, 21:139-46
40. Kokawa A, Kondo H, Gotoda T, Ono H, Saito D, Nakadaira S, Kosuge
T and Yoshida S Increased expression of cyclooxygenase-2 in
human pancreatic neoplasms and potential for chemopre-
vention by cyclooxygenase inhibitors. Cancer 2001, 91:333-8
41. Merati K, said Siadaty M, Andea A, Sarkar F, Ben-Josef E, Mohammad
R, Philip P, Shields AF, Vaitkevicius V, Grignon DJ and Adsay NV Ex-
pression of inflammatory modulator COX-2 in pancreatic
ductal adenocarcinoma and its relationship to pathologic
and clinical parameters. Am J Clin Oncol 2001, 24:447-52
42. Maitra A, Ashfaq R, Gunn CR, Rahman A, Yeo CJ, Sohn TA, Cameron
JL, Hruban RH and Wilentz RE Cyclooxygenase 2 expression in
pancreatic adenocarcinoma and pancreatic intraepithelial
neoplasia: an immunohistochemical analysis with automat-
ed cellular imaging. Am J Clin Pathol 2002, 118:194-201
43. Ding XZ, Tong WG and Adrian TE Blockade of cyclooxygenase-
2 inhibits proliferation and induces apoptosis in human pan-
creatic cancer cells. Anticancer Res 2000, 20:2625-31
44. Nzeako UC and Gores GJ Increased expression of cyclooxyge-
nase-2 in human pancreatic neoplasms and potential for che-
moprevention by cyclooxygenase inhibitors.  Cancer 2002,
94:1903-4
45. Ding XZ, Iversen P, Cluck MW, Knezetic JA and Adrian TE Lipoxy-
genase inhibitors abolish proliferation of human pancreatic
cancer cells. Biochem Biophys Res Commun 1999, 261:218-23
46. Hennig R, Ding XZ, Tong WG, Schneider MB, Standop J, Friess H,
Buchler MW, Pour PM and Adrian TE 5-Lipoxygenase and leuko-
triene B(4) receptor are expressed in human pancreatic can-
cers but not in pancreatic ducts in normal tissue. Am J Pathol
2002, 161:421-8
47. Bleich D, Chen S, Gu JL and Nadler JL The role of 12-lipoxygenase
in pancreatic-cells (Review). Int J Mol Med 1998, 1:265-72
48. Yip-Schneider MT, Barnard DS, Billings SD, Cheng L, Heilman DK, Lin
A, Marshall SJ, Crowell PL, Marshall MS and Sweeney CJ Cyclooxy-
genase-2 expression in human pancreatic adenocarcinomas.
Carcinogenesis 2000, 21:139-46
49. Anderson KM, Seed T, Meng J, Ou D, Alrefai WA and Harris JE Five-
lipoxygenase inhibitors reduce Panc-1 survival: the mode of
cell death and synergism of MK886 with gamma linolenic ac-
id. Anticancer Res 1998, 18(2A):791-800
50. Anderson KM, Alrefai WA, Bonomi P, Dudeja P, Ou D, Anderson C
and Harris JE Altered oncogene, tumor suppressor and cell-cy-
cle gene expression in PANC-1 cells cultured with the pleio-
trophic 5-lipoxygenase inhibitor, MK886, assessed with a
gene chip. Anticancer Res 1999, 19(5B):3873-87
51. Harris JE, Alrefai WA, Meng J and Anderson KM Five-lipoxygenase
inhibitors reduce Panc-1 survival: synergism of MK886 with
gamma linolenic acid. Adv Exp Med Biol 1999, 469:505-10
52. Ding XZ, Kuszynski CA, El-Metwally TH and Adrian TE Lipoxygen-
ase inhibition induced apoptosis, morphological changes,
and carbonic anhydrase expression in human pancreatic can-
cer cells. Biochem Biophys Res Commun 1999, 266:392-9
53. Tong WG, Ding XZ, Witt RC and Adrian TE Lipoxygenase Inhib-
itors Attenuate Growth of Human Pancreatic Cancer Xe-
nografts and Induce Apoptosis through the Mitochondrial
Pathway. Mol Cancer Ther 2002, 1:929-935
54. Tong WG, Ding XZ and Adrian TE The mechanisms of lipoxyge-
nase inhibitor-induced apoptosis in human breast cancer
cells. Biochem Biophys Res Commun 2002, 296:942-8
55. Pour P, Althoff J, Kruger FW and Mohr U A potent pancreatic car-
cinogen in Syrian hamsters: N-nitrosobis(2-oxopro-
pyl)amine. J Natl Cancer Inst 1977, 58(5):1449-53
56. Egami H, Takiyama Y, Chaney WG, Cano M, Fujii H, Tomioka T,
Metzgar R and Pour PM Comparative studies on expression of
tumor-associated antigens in human and induced pancreatic
cancer in Syrian hamsters. Int J Pancreatol 1990, 7(1–3):91-100
57. Ishikawa O, Ohigashi H, Imaoka S, Nakai I, Mitsuo M, Weide L and
Pour PM The role of pancreatic islets in experimental pancre-
atic carcinogenicity. Am J Pathol 1995, 147:1456-64
58. Takahashi M, Furukawa F, Toyoda K, Sato H, Hasegawa R, Imaida K
and Hayashi Y Effects of various prostaglandin synthesis inhib-
itors on pancreatic carcinogenesis in hamsters after initia-
tion with N-nitrosobis(2-oxopropyl)amine. Carcinogenesis 1990,
11(3):393-5
59. Wenger FA, Kilian M, Achucarro P, Heinicken D, Schimke I, Guski H,
Jacobi CA and Muller JM Effects of Celebrex and Zyflo on BOP-
induced pancreatic cancer in Syrian hamsters. Pancreatology
2002, 2:54-60
60. Gunning WT, Kramer PM, Steele VE and Pereira MA Chemopre-
vention by lipoxygenase and leukotriene pathway inhibitors
of vinyl carbamate-induced lung tumors in mice. Cancer Res
2002, 62:4199-4201
61. Yano T, Zissel G, Muller-Qernheim J, Jae Shin S, Satoh H and Ichikawa
T Prostaglandin E2 reinforces the activation of Ras signal
pathway in lung adenocarcinoma cells via EP3. FEBS Lett 2002,
518:154-158
62. Pai R, Soreghan B, Szabo IL, Pavelka M, Baatar D and Tarnawski AS
Prostaglandin E2 transactivates EGF receptor: a novel
mechanism for promoting colon cancer growth and gas-
trointestinal hypertrophy. Nat Med 2002, 8:289-293
63. Fiebich BL, Schleicher S, Spleiss O, Czygan M and Hull M Mecha-
nisms of prostaglandin E2-induced interleukin-6 release in
astrocytes: possible involvement of EP4-like receptors, p38
mitogen-activated protein kinase and protein kinase C: J Neu-
rochem 2001, 79:950-958
64. Pai R, Szabo IL, Soreghan BA, Atay S, Kawanaka H and Tarnawski AS
PGE(2) stimulates VEGF expression in endothelial cells via
ERK2/JNK1 signaling pathways.  Biochem Biophys Res Commun
2001, 286:923-928
65. Fujino H, West KA and Regan JW Phosphorylation of glycogen
synthase kinase-3 and stimulation of T-cell factor signaling
following activation of EP2 and EP4 prostanoid receptors by
prostaglandin E2. J Biol Chem 2002, 277:2614-2619
66. Liu XH, Kirschenbaum A, Lu M, Yao S, Klausner A, Preston C, Hol-
land JF and Levine AC Prostaglandin E(2) stimulates prostatic
intraepithelial neoplasia cell growth through activation of
the interleukin-6/GP130/STAT-3 signaling pathway. Biochem
Biophys Res Commun 2002, 290:249-255
67. Bishop-Bailey D, Calatayud S, Warner TD, Hla T and Mitchell JA
Prostaglandins and the regulation of tumor growth. J Environ
Pathol Toxicol Oncol 2002, 21:93-101
68. Breyer RM Prostaglandin EP(1) receptor subtype selectivity
takes shape. Mol Pharmacol 2001, 59:1357-9
69. Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya
S, Oshima M and Taketo MM Acceleration of intestinal polyposis
through prostaglandin receptor EP2 in Apc(Delta 716)
knockout mice. Nat Med 2001, 7:1048-51
70. Rodrigues S, Nguyen QD, Faivre S, Bruyneel E, Thim L, Westley B,
May F, Flatau G, Mareel M, Gespach C and Emami S Activation of
cellular invasion by trefoil peptides and src is mediated by cy-
clooxygenase- and thromboxane A2 receptor-dependent
signaling pathways. FASEB J 2001, 15:1517-28
71. Nie D, Lamberti M, Zacharek A, Li L, Szekeres K, Tang K, Chen Y and
Honn KV Thromboxane A(2) regulation of endothelial cell
migration, angiogenesis, and tumor metastasis. Biochem Bio-
phys Res Commun 2000, 267:245-51
72. Kasahara K, Fujimura M, Bando T, Shibata K, Shirasaki H and Matsuda
T Modulation of sensitivity to cis-diamminedichloroplatinum
(II) by thromboxane A2 receptor antagonists in non-small
lung cell lines. Br J Cancer 1996, 74:1553-8
73. Rodrigues S, Nguyen QD, Faivre S, Bruyneel E, Thim L, Westley B,
May F, Flatau G, Mareel M, Gespach C and Emami S Activation ofMolecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/10
Page 11 of 12
(page number not for citation purposes)
cellular invasion by trefoil peptides and src is mediated by cy-
clooxygenase- and thromboxane A2 receptor-dependent
signaling pathways. FASEB J 2001, 15:1517-28
74. Fujimura M, Kasahara K, Shirasaki H, Heki U, Iwasa K, Ueda A and
Matsuda T Up-regulation of ICH-1L protein by thromboxane
A2 antagonists enhances cisplatin-induced apoptosis in non-
small-cell lung-cancer cell lines. J Cancer Res Clin Oncol 1999,
125:389-94
75. Pakala R and Benedict CR Effect of serotonin and thromboxane
A2 on endothelial cell proliferation: effect of specific recep-
tor antagonists. J Lab Clin Med 1998, 131:527-37
76. Ding XZ, Tong WG and Adrian TE 12-lipoxygenase metabolite,
12(S)-HETE stimulates pancreatic cancer cell proliferation.
Involvement of tyrosine phosphorylation and MEK/ERK acti-
vation. Int J Cancer 2001, 94:630-636
77. Ding XZ, Tong WG and Adrian TE Interaction between the 5-
lipoxygenase and EGF-mediated signaling pathways is im-
portant in the control of pancreatic cancer cell proliferation.
Pancreas 2001, 23:434
78. Adrian TE, Ding XZ and Tong WG The mitogenic effect of 5-
lipoxygenase metabolite, 5-HETE on pancreatic cancer cell
proliferation through activation of multiple signaling path-
ways. FASEB J 2001, 15:A1163
79. Tong WG, Ding XZ, Hennig R, Witt RC, Standop J, Pour PM and
Adrian TE Leukotriene B4 Receptor Antagonist LY293111 In-
hibits Proliferation and Induces Apoptosis in Human Pancre-
atic Cancer Cells. Clin Cancer Res 2002, 8:3232-3242
80. Szekeres CK, Tang K, Trikha M and Honn KV Eicosanoid activa-
tion of extracellular signal-regulated kinase1/2 in human ep-
idermoid carcinoma cells. J Biol Chem 2000, 275:38831-3841
81. Liu B, Maher RJ, De Jonckheere JP, Popat RU, Stojakovic S, Hannun
YA, Porter AT and Honn KV 12(S)-HETE increases the motility
of prostate tumor cells through selective activation of PKC
alpha. Adv Exp Med Biol 1997, 400B:707-718
82. Liu B, Khan WA, Hannun YA, Timar J, Taylor JD, Lundy S, Butovich I
and Honn KV 12(S)-hydroxyeicosatetraenoic acid and 13(S)-
hydroxyoctadecadienoic acid regulation of protein kinase C-
alpha in melanoma cells: role of receptor-mediated hydroly-
sis of inositol phospholipids.  Proc Natl Acad Sci U S A 1995,
92:9323-9327
83. Li M, Wu X and Xu XC Induction of apoptosis by cyclo-oxyge-
nase-2 inhibitor NS398 through a cytochrome C-dependent
pathway in esophageal cancer cells. Int J Cancer 2001, 93:218-23
84. Li M, Wu X and Xu XC Induction of apoptosis in colon cancer
cells by cyclooxygenase-2 inhibitor NS398 through a cyto-
chrome c-dependent pathway. Clin Cancer Res 2001, 7:1010-6
85. Aggarwal S, Taneja N, Lin L, Orringer MB, Rehemtulla A and Beer DG
Indomethacin-induced apoptosis in esophageal adenocarci-
noma cells involves upregulation of Bax and translocation of
mitochondrial cytochrome C independent of COX-2 expres-
sion. Neoplasia 2000, 2(4):346-56
86. Munkarah AR, Morris R, Baumann P, Deppe G, Malone J, Diamond MP
and Saed GM Effects of prostaglandin E(2) on proliferation and
apoptosis of epithelial ovarian cancer cells. J Soc Gynecol Investig
2002, 9:168-73
87. Lin MT, Lee RC, Yang PC, Ho FM and Kuo ML Cyclooxygenase-2
inducing Mcl-1-dependent survival mechanism in human
lung adenocarcinoma CL1.0 cells. Involvement of phosphati-
dylinositol 3-kinase/Akt pathway. J Biol Chem 2001, 276:48997-
9002
88. Nzeako UC, Guicciardi ME, Yoon JH, Bronk SF and Gores GJ COX-
2 inhibits Fas-mediated apoptosis in cholangiocarcinoma
cells. Hepatology 2002, 35:552-9
89. Tang X, Sun YJ, Half E, Kuo MT and Sinicrope F Cyclooxygenase-2
overexpression inhibits death receptor 5 expression and
confers resistance to tumor necrosis factor-related apopto-
sis-inducing ligand-induced apoptosis in human colon cancer
cells. Cancer Res 2002, 62:4903-8
90. He Q, Luo X, Huang Y and Sheikh MS Apo2L/TRAIL differentially
modulates the apoptotic effects of sulindac and a COX-2 se-
lective non-steroidal anti-inflammatory agent in Bax-defi-
cient cells. Oncogene 2002, 21:6032-40
91. Chan TA Nonsteroidal anti-inflammatory drugs, apoptosis,
and colon-cancer chemoprevention. Lancet Oncol 2002, 3:166-
74
92. Thun MJ, Henley SJ and Patrono C Nonsteroidal anti-inflamma-
tory drugs as anticancer agents: mechanistic, pharmacolog-
ic, and clinical issues. J Natl Cancer Inst 2002, 94:252-66
93. Hsu AL, Ching TT, Wang DS, Song X, Rangnekar VM and Chen CS
The cyclooxygenase-2 inhibitor celecoxib induces apoptosis
by blocking Akt activation in human prostate cancer cells in-
dependently of Bcl-2. J Biol Chem 2000, 275:11397-403
94. Shimada T, Hiraishi H and Terano A Hepatocyte growth factor
protects gastric epithelial cells against ceramide-induced ap-
optosis through induction of cyclooxygenase-2. Life Sci 2000,
68:539-46
95. Chan TA, Morin PJ, Vogelstein B and Kinzler KW Mechanisms un-
derlying nonsteroidal antiinflammatory drug-mediated ap-
optosis. Proc Natl Acad Sci U S A 1998, 95:681-6
96. Pidgeon GP, Kandouz M, Meram A and Honn KV Mechanisms con-
trolling cell cycle arrest and induction of apoptosis after 12-
lipoxygenase inhibition in prostate cancer cells.  Cancer Res
2002, 62:2721-7
97. Wong BC, Wang WP, Cho CH, Fan XM, Lin MC, Kung HF and Lam
SK 12-Lipoxygenase inhibition induced apoptosis in human
gastric cancer cells. Carcinogenesis 2001, 22:1349-54
98. Tang DG, Chen YQ and Honn KV Arachidonate lipoxygenases as
essential regulators of cell survival and apoptosis. Proc Natl
Acad Sci U S A 1996, 93:5241-6
99. Rozic JG, Chakraborty C and Lala PK Cyclooxygenase inhibitors
retard murine mammary tumor progression by reducing tu-
mor cell migration, invasiveness and angiogenesis. Int J Cancer
2001, 93:497-506
100. Sheng H, Shao J, Washington MK and DuBois RN Prostaglandin E2
increases growth and motility of colorectal carcinoma cells.
J Biol Chem 2001, 276:18075-81
101. Gately S The contributions of cyclooxygenase-2 to tumor an-
giogenesis. Cancer Metastasis Rev 2000, 19:19-27
102. Pan MR, Chuang LY and Hung WC Non-steroidal anti-inflamma-
tory drugs inhibit matrix metalloproteinase-2 expression via
repression of transcription in lung cancer cells. FEBS Lett 2001,
508:365-8
103. Jiang MC, Liao CF and Lee PH Aspirin inhibits matrix metallo-
proteinase-2 activity, increases E-cadherin production, and
inhibits in vitro invasion of tumor cells. Biochem Biophys Res Com-
mun 2001, 282:671-7
104. Attiga FA, Fernandez PM, Weeraratna AT, Manyak MJ and Patierno
SR Inhibitors of prostaglandin synthesis inhibit human pros-
tate tumor cell invasiveness and reduce the release of matrix
metalloproteinases. Cancer Res 2000, 60:4629-37
105. Fosslien E Review: molecular pathology of cyclooxygenase-2
in cancer-induced angiogenesis. Ann Clin Lab Sci 2001, 31:325-48
106. Gately S The contributions of cyclooxygenase-2 to tumor an-
giogenesis. Cancer Metastasis Rev 2000, 19(1–2):19-27
107. Masferrer JL, Koki A and Seibert K COX-2 inhibitors. A new class
of antiangiogenic agents. Ann N Y Acad Sci 1999, 889:84-6
108. Sonoshita M, Takaku K, Sasaki N, Sugimoto Y, Ushikubi F, Narumiya
S, Oshima M and Taketo MM Acceleration of intestinal polyposis
through prostaglandin receptor EP2 in Apc(Delta 716)
knockout mice. Nat Med 2001, 7:1048-51
109. Daniel TO, Liu H, Morrow JD, Crews BC and Marnett LJ Throm-
boxane A2 is a mediator of cyclooxygenase-2-dependent en-
dothelial migration and angiogenesis. Cancer Res 1999, 59:4574-
7
110. Spisni E, Griffoni C, Santi S, Riccio M, Marulli R, Bartolini G, Toni M,
Ullrich V and Tomasi V Colocalization prostacyclin (PGI2) syn-
thase – caveolin-1 in endothelial cells and new roles for PGI2
in angiogenesis. Exp Cell Res 2001, 266:31-43
111. Ali S, Davis MG, Becker MW and Dorn GW 2nd Thromboxane A2
stimulates vascular smooth muscle hypertrophy by up-regu-
lating the synthesis and release of endogenous basic fibrob-
last growth factor. J Biol Chem 1993, 268:17397-403
112. Chen G, Wilson R, McKillop JH and Walker JJ The role of cy-
tokines in the production of prostacyclin and thromboxane
in human mononuclear cells. Immunol Invest 1994, 23:269-79
113. Bartolini G, Orlandi M, Chiricolo M, Minghetti L, Guerrini F, Fidan M,
Franceschi C and Tomasi V Regulation of thromboxane A2 bio-
synthesis in platelet-free human monocytes and the possible
role of polypeptide growth factor(s) in the induction of cy-
clooxygenase system. Biochim Biophys Acta 1986, 876:486-93Publish with BioMed Central    and   every 
scientist can read your work free of charge
"BioMed Central will be the most significant development for 
disseminating the results of biomedical research in our lifetime."
Sir Paul Nurse, Cancer Research UK
Your research papers will be:
available free of charge to the entire biomedical community
peer reviewed and published  immediately upon acceptance
cited in PubMed and archived on PubMed Central 
yours — you keep the copyright
Submit your manuscript here:
http://www.biomedcentral.com/info/publishing_adv.asp
BioMedcentral
Molecular Cancer 2003, 2 http://www.molecular-cancer.com/content/2/1/10
Page 12 of 12
(page number not for citation purposes)
114. Dethlefsen SM, Shepro D and D'Amore PA Arachidonic acid me-
tabolites in bFGF-, PDGF-, and serum-stimulated vascular
cell growth. Exp Cell Res 1994, 12:262-73
115. Nie D, Tang K, Diglio C and Honn KV Eicosanoid regulation of
angiogenesis: role of endothelial arachidonate 12-lipoxygen-
ase. Blood 2000, 95:2304-11
116. Nie D, Tang K, Szekeres K, Li L and Honn KV Eicosanoid regula-
tion of angiogenesis in human prostate carcinoma and its
therapeutic implications. Ann N Y Acad Sci 2000, 905:165-76
117. Nie D, Hillman GG, Geddes T, Tang K, Pierson C, Grignon DJ and
Honn KV Platelet-type 12-lipoxygenase regulates angiogen-
esis in human prostate carcinoma.  Adv Exp Med Biol 1999,
469:623-30
118. Nie D, Hillman GG, Geddes T, Tang K, Pierson C, Grignon DJ and
Honn KV Platelet-type 12-lipoxygenase in a human prostate
carcinoma stimulates angiogenesis and tumor growth. Cancer
Res 1998, 58:4047-51
119. O'Byrne KJ and Dalgleish AG Chronic immune activation and in-
flammation as the cause of malignancy.  Br J Cancer 2001,
85:473-83
120. Goodwin JS and Ceuppens J Regulation of the immune response
by prostaglandins. J Clin Immunol 1983, 3:295-315
121. Ceuppens J and Goodwin J Prostaglandins and the immune re-
sponse to cancer. Anticancer Res 1981, 1:71-8
122. Farrow B and Evers BM Inflammation and the development of
pancreatic cancer. Surg Oncol 2002, 10:153-69
123. Joshi PC, Zhou X, Cuchens M and Jones Q Prostaglandin E2 sup-
pressed IL-15-mediated human NK cell function through
down-regulation of common gamma-chain. J Immunol 2001,
166:885-91
124. Lala PK and Chakraborty C Role of nitric oxide in carcinogenesis
and tumour progression. Lancet Oncol 2001, 2:149-56
125. Jadeski LC, Hum KO, Chakraborty C and Lala PK Nitric oxide pro-
motes murine mammary tumour growth and metastasis by
stimulating tumour cell migration, invasiveness and angio-
genesis. Int J Cancer 2000, 86:30-9
126. Kong G, Kim EK, Kim WS, Lee KT, Lee YW, Lee JK, Paik SW and
Rhee JC Role of cyclooxygenase-2 and inducible nitric oxide
synthase in pancreatic cancer.  J Gastroenterol Hepatol 2002,
17:914-21
127. de Ledinghen V, Liu H, Zhang F, Lo CR, Subbaramaiah K, Dannenberg
AJ and Czaja MJ Induction of cyclooxygenase-2 by tumor pro-
moters in transformed and cytochrome P450 2E1-express-
ing hepatocytes. Carcinogenesis 2002, 23:73-9
128. Keith RL, Miller YE, Hoshikawa Y, Moore MD, Gesell TL, Gao B, Mal-
kinson AM, Golpon HA, Nemenoff RA and Geraci MW Manipula-
tion of pulmonary prostacyclin synthase expression prevents
murine lung cancer. Cancer Res 2002, 62:734-40
129. Degen GH SEMV cell cultures: a model for studies of prostag-
landin-H synthase-mediated metabolism and genotoxicity of
xenobiotics. Toxicol Lett 1993, 67:187-200
130. Marnett LJ Prostaglandin synthase-mediated metabolism of
carcinogens and a potential role for peroxyl radicals as reac-
tive intermediates. Environ Health Perspect 1990, 88:5-12
131. Schuller HM, Zhang L, Weddle DL, Castonguay A, Walker K and Mill-
er MS The cyclooxygenase inhibitor ibuprofen and the FLAP
inhibitor MK886 inhibit pancreatic carcinogenesis induced in
hamsters by transplacental exposure to ethanol and the to-
bacco carcinogen NNK. J Cancer Res Clin Oncol 2002, 128:525-32
132. Castonguay A, Rioux N, Duperron C and Jalbert G Inhibition of
lung tumorigenesis by NSAIDS: a working hypothesis. Exp
Lung Res 1998, 24:605-15
133. Schuller HM, Tithof PK, Williams M and Plummer H 3rd The tobac-
co-specific carcinogen 4-(methylnitrosamino)-1-(3-pyridyl)-
1-butanone is a beta-adrenergic agonist and stimulates DNA
synthesis in lung adenocarcinoma via beta-adrenergic recep-
tor-mediated release of arachidonic acid.  Cancer Res 1999,
59:4510-5
134. Smith TJ, Stoner GD and Yang CS Activation of 4-(methylnitro-
samino)-1-(3-pyridyl)-1-butanone (NNK) in human lung mi-
crosomes by cytochromes P450, lipoxygenase, and
hydroperoxides. Cancer Res 1995, 55:5566-73
135. Bhat KP and Pezzuto JM Cancer chemopreventive activity of
resveratrol. Ann N Y Acad Sci 2002, 957:210-29
136. Dirsch VM and Vollmar AM Ajoene, a natural product with non-
steroidal anti-inflammatory drug (NSAID)-like properties.
Biochem Pharmacol 2001, 61:587-93
137. Pinto JT, Lapsia S, Shah A, Santiago H and Kim G Antiproliferative
effects of garlic-derived and other allium related com-
pounds. Adv Exp Med Biol 2001, 492:83-106
138. Yang CS, Maliakal P and Meng X Inhibition of carcinogenesis by
tea. Annu Rev Pharmacol Toxicol 2002, 42:25-54
139. Wargovich MJ, Woods C, Hollis DM and Zander ME Herbals, can-
cer prevention and health. J Nutr 2001, 131(11 Suppl):3034S-6S
140. Hwang DH, Fung V and Dannenberg AJ National Cancer Institute
workshop on chemopreventive properties of nonsteroidal
anti-inflammatory drugs: role of COX-dependent and -inde-
pendent mechanisms. Neoplasia 2002, 4:91-97